Phase II Trial of Conformal Radiation Therapy for Pediatric Low-Grade Glioma

Targeted therapy in pediatric low-grade glioma.

Collectively, pediatric low-grade gliomas account for most brain tumors reported in children. Surgery is typically curable for operable lesions. However, more effective therapies are required for inaccessible tumors, both to overcome refractory disease and to minimize the toxicity associated with conventional adjuvant chemotherapy and radiotherapy regimens. Recent years have witnessed rapid imp...

A treatment planning comparison of highly conformal radiation therapy for pediatric low-grade brainstem gliomas

Intensity modulated radiation therapy versus three‐dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison

The present study compared the dosimetry of intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) techniques in patients treated for high-grade glioma. A total of 20 patients underwent computed tomography treatment planning in conjunction with magnetic resonance imaging fusion. Prescription dose and normal-tissue constraints were identical for t...

First experiences in treatment of low-grade glioma grade I and II with proton therapy

BACKGROUND To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II). PATIENTS AND METHODS Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases proton therapy was performed due to tumor progression after biopsy, in 8 cases each d...

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.

BACKGROUND A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG). METHODS Sixty patients with recurrent HGG received temozolomide at 150 mg/m(2)/day on days 1-7 and days 15-21 during each 4-week cycle. The primary endpoint was 6-month progression-free survival (PFS-6), with a ...